Compare Ascendis Pharma A/S (ASND) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Centrus Energy Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Centrus Energy Corp trades at $169.54 (market cap $3.37B). The key difference: Ascendis Pharma A/S is far larger — about 5.3× Centrus Energy Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| ASND | LEU | |
|---|---|---|
Market Cap | $17.74B | $3.37B |
Sector | Health | Energy |
52-Week High | $277.18 | $436.00 |
52-Week Low | $163.32 | $146.61 |
Enterprise Value | $18.11B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Centrus Energy (LEU) trades at $171.05, down 1.45% on the day, with a neutral technical outlook. The company recently secured a major Department of Energy contract valued over $1 billion and is set to join the S&P SmallCap 600 index. While Q1 2026 earnings beat expectations, Q4 2025 was a significant miss. Valuation ratios appear elevated with a P/E of 62.2 and P/S of 8.05. Operating cash flow was positive in 2025 but turned negative in 2026 projections.
The outlook is mixed; strong government contracts and index inclusion provide tailwinds, but high valuation and inconsistent earnings pose risks. Analyst consensus is a Buy with a $224.50 price target, suggesting potential upside, though execution on new contracts and profitability trends will be critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
